Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12610000652077
ACTRN12610000652077
Completed
Phase 3

In adolescents with Attention Deficit Hyperactivity Disorder (ADHD), how does methylphenidate compared to placebo, effect Blood Oxygenation Level Dependent (BOLD) response as measured by functional Magnetic Resonance Imaging (fMRI), and how does the response vary with difference in the dopamine transporter (DAT1) gene.

Dr. Tim Silk0 sites36 target enrollmentAugust 11, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr. Tim Silk
Enrollment
36
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2010
End Date
October 3, 2012
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr. Tim Silk

Eligibility Criteria

Inclusion Criteria

  • •ADHD (combined type)
  • •Healthy, matched control adolescents (Placebo only)
  • •right handed

Exclusion Criteria

  • •Weight under 35kg
  • •Full scale Intelligence Quotient (FSIQ) \>70
  • •Conners Parent Rating Scale (CPRS) \>65 for ADHD, \<60 for controls
  • •gluten intolerance (due to presence in placebo)
  • •wearing dental braces
  • •no reading disabilities,
  • •no comorbidities, of major depression, Autism Spectrum Disorders, or psychosis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
erofeeback Training (NFT) of ADHD child at homeADHDADHD hyperactiveD046650
JPRN-jRCT1030220201Tazaki Miyako8
Not Yet Recruiting
Phase 3
Identification of Attention Deficit Hyperactivity Disorder using Parent-Teacher administered ADHD Rating Scale-IV among Pre-school going children to know the prevalence of this disorder in Belagavi city.
CTRI/2023/07/054991KAHER Institute Of Physiotherapy
Active, Not Recruiting
N/A
Attention Deficit Hyperactivity Disorder (ADHD) and opioid maintenance therapy.A randomized, placebo-controlled study of the efficacy of atomoxetine for treating adult ADHD in patients receiving opioid maintenance therapyPatients will be recruited from out-patient clinics treating opioid dependent patients with buprenorphine or methadone maintenance therapy. Patients will be screened for ADHD symptoms. Based on the screen results, patients will undergo medical and psychiatric assessment to identify those meeting the criteria for adult ADHD. Patients diagnosed with comorbid ADHD and opioid dependence will then be randomized into atomoxetine and placebo study groups.MedDRA version: 12.1Level: LLTClassification code 10064104Term: ADHD
EUCTR2010-019981-94-FIHUS/ Neuropsykiatrian poliklinikka30
Recruiting
Phase 2
Attention Defficity Hyperactivity Disorder and fMRI neurofeedback: A randomized controlled trial on the effects of self-modulating anterior cingulate cortex activation levels.
NL-OMON37512niversitair Medisch Centrum Sint Radboud
Completed
N/A
Attention deficit hyperactivity disorder, developmental coordination disorder, and the cognitive orientation to daily occupational performance approach: Is there a role for diagnostic profiling and treatment to improve mental health outcomes?Attention Deficit Hyperactivity DisorderDevelopmental Coordination DisorderMental Health - Other mental health disordersPhysical Medicine / Rehabilitation - Occupational therapy
ACTRN12618001972213a Trobe University19